Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q347941> ?p ?o }
Showing triples 1 to 59 of
59
with 100 triples per page.
- Q347941 subject Q6870315.
- Q347941 subject Q7215001.
- Q347941 subject Q7570636.
- Q347941 subject Q9454024.
- Q347941 subject Q9546190.
- Q347941 abstract "Template:ForParecoxib is a water-soluble and injectable prodrug of valdecoxib. It is marketed as Dynastat in the European Union. Parecoxib is a COX2 selective inhibitor in the same category as celecoxib (Celebrex) and rofecoxib (Vioxx). As it is injectable, it can be used perioperatively when patients are unable to take oral medications. It is approved through much of Europe for short term perioperative pain control much in the same way ketorolac (Toradol) is used in the United States. However, unlike ketorolac, parecoxib has no effect on platelet function and therefore does not promote bleeding during or after surgery. In addition, ketorolac has a much higher gastrointestinal toxicity profile compared to most other nonsteroidal antiinflammatory drugs (NSAIDs) including ibuprofen and naprosyn. However, in the United States ketorolac is the only injectable NSAID, although it is banned in many European countries due to concerns about surgical bleeding and stomach ulcers after surgery.In 2005, the U.S. Food and Drug Administration (FDA) issued a letter of non-approval for parecoxib in the United States. No reasons were ever documented publicly for the non-approval, although one study noted increased occurrences of heart attacks following cardiac bypass surgery compared to placebo when high doses of parecoxib were used to control pain after surgery. It is also important to remember that rare but severe allergic reactions (Stevens-Johnson Syndrome, Lyell Syndrome) have been described with valdecoxib, the molecule to which parecoxib is converted. The drug is not approved for use after cardiac surgery in Europe. Ketorolac, still banned in much of Europe, and IV Ibuprofen are therefore the only options for IV NSAIDs in the United States, and it is not clear whether parecoxib will be resubmitted to the FDA in the future.All anti-inflammatory medications in the U.S. carry the same warning regarding skin reactions, and none are approved for use during CABG surgery, so the reason for the FDA denying the approval of parecoxib remains unknown, but was likely related to political pressure from the US Congress to not approve another COX-2 selective inhibitor in the wake of the Vioxx affair. No COX-2 selective inhibitor has been approved in the US since that time, regardless of the safety profile of parecoxib in Europe. Efforts to find out the scientific rationale, or more likely the lack thereof, that the FDA used to justify the non-approval of parecoxib in the USA have proven futile due to secrecy issues.".
- Q347941 atcPrefix "M01".
- Q347941 atcSuffix "AH04".
- Q347941 bioavailability "100.0".
- Q347941 casNumber "202409-33-4".
- Q347941 chEBI "73038".
- Q347941 drugbank "DB08439".
- Q347941 fdaUniiCode "9TUW81Y3CE".
- Q347941 iupacName "N-{[4-(5-methyl-3-phenylisoxazol-4-yl)phenyl]".
- Q347941 iupacName "sulfonyl}propanamide".
- Q347941 pubchem "119828".
- Q347941 thumbnail Parecoxib.svg?width=300.
- Q347941 wikiPageWikiLink Q101026.
- Q347941 wikiPageWikiLink Q14864419.
- Q347941 wikiPageWikiLink Q14916181.
- Q347941 wikiPageWikiLink Q188724.
- Q347941 wikiPageWikiLink Q2014797.
- Q347941 wikiPageWikiLink Q204711.
- Q347941 wikiPageWikiLink Q347613.
- Q347941 wikiPageWikiLink Q377458.
- Q347941 wikiPageWikiLink Q407693.
- Q347941 wikiPageWikiLink Q408801.
- Q347941 wikiPageWikiLink Q411412.
- Q347941 wikiPageWikiLink Q422956.
- Q347941 wikiPageWikiLink Q432083.
- Q347941 wikiPageWikiLink Q458.
- Q347941 wikiPageWikiLink Q5281998.
- Q347941 wikiPageWikiLink Q603741.
- Q347941 wikiPageWikiLink Q640448.
- Q347941 wikiPageWikiLink Q6870315.
- Q347941 wikiPageWikiLink Q7215001.
- Q347941 wikiPageWikiLink Q7570636.
- Q347941 wikiPageWikiLink Q9368.
- Q347941 wikiPageWikiLink Q9377.
- Q347941 wikiPageWikiLink Q9454024.
- Q347941 wikiPageWikiLink Q9546190.
- Q347941 atcPrefix "M01".
- Q347941 atcSuffix "AH04".
- Q347941 bioavailability "100.0".
- Q347941 casNumber "202409".
- Q347941 chebi "73038".
- Q347941 drugbank "DB08439".
- Q347941 iupacName "N-{[4-phenyl]".
- Q347941 iupacName "sulfonyl}propanamide".
- Q347941 pubchem "119828".
- Q347941 unii "9".
- Q347941 type ChemicalSubstance.
- Q347941 type Drug.
- Q347941 type ChemicalObject.
- Q347941 type Thing.
- Q347941 type Q8386.
- Q347941 comment "Template:ForParecoxib is a water-soluble and injectable prodrug of valdecoxib. It is marketed as Dynastat in the European Union. Parecoxib is a COX2 selective inhibitor in the same category as celecoxib (Celebrex) and rofecoxib (Vioxx). As it is injectable, it can be used perioperatively when patients are unable to take oral medications. It is approved through much of Europe for short term perioperative pain control much in the same way ketorolac (Toradol) is used in the United States.".
- Q347941 label "Parecoxib".
- Q347941 depiction Parecoxib.svg.